Ligand Pharmaceuticals Incorporated  (LGND)
Other Ticker:  
Price: $69.8900 $1.36 1.985%
Day's High: $71.155 Week Perf: -11.39 %
Day's Low: $ 68.50 30 Day Perf: -4.4 %
Volume (M): 141 52 Wk High: $ 94.57
Volume (M$): $ 9,827 52 Wk Avg: $68.48
Open: $68.50 52 Wk Low: $49.24

 Market Capitalization (Millions $) 1,215
 Shares Outstanding (Millions) 17
 Employees 149
 Revenues (TTM) (Millions $) 130
 Net Income (TTM) (Millions $) 16
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 5

Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc. is a biopharmaceutical company that was founded in 1987 and is based in San Diego, California. The company's primary focus is on developing innovative medicines to treat serious diseases, and it has a diversified portfolio of drugs in various stages of development.

Ligand's primary area of expertise is in developing small molecule drugs that can selectively target specific cellular pathways to treat diseases. The company's technology platform is based on its proprietary Captisole technology, which is a drug delivery technology that improves the solubility and bioavailability of drugs. This technology has been licensed to various pharmaceutical companies for the development of their own drugs.

The company has a broad portfolio of drugs that are either in clinical trials or have been approved by regulatory agencies. Ligand's current portfolio includes drugs for the treatment of cancer, inflammatory diseases, metabolic disorders, and other diseases. Some of the drugs in the company's portfolio include Promactae (eltrombopag), Amgen's Omecamtiv Mecarbil (a cardiac muscle activator), and Evomelae (melphalan hydrochloride), among others.

Ligand has a business model that involves licensing its technology and intellectual property to pharmaceutical companies for the development of their own drugs. This allows the company to generate royalties and other revenue streams from these partnerships. It also allows the company to diversify its pipeline and reduce its reliance on any individual drug or therapeutic area.

The company has received numerous awards and recognitions for its innovative technology and drug development programs. In 2020, Ligand was named to Forbes America's Best Small Companies list, and its Captisole technology was named one of R&D Magazine's 100 most significant innovations of the year.

Overall, Ligand Pharmaceuticals Inc. is a leading biopharmaceutical company that is focused on developing innovative drugs to treat serious diseases. The company's technology platform and diversified pipeline make it a strong candidate for continued growth and success in the biotech industry.

   Company Address: 3911 Sorrento Valley Boulevard, Suite 110 San Diego 92121 CA
   Company Phone Number: 550-7500   Stock Exchange / Ticker: NASDAQ LGND
   LGND is expected to report next financial results on May 07, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Issue News

Ligand Pharmaceuticals Empowers Non-Executive Employees with Stock Options and Units, Strengthening Commitment to Shareholder Value and Workforce Development

Published Thu, Feb 1 2024 10:00 PM UTC

Ligand Pharmaceuticals Grants Stock Options and Units to Non-Executive Employees
SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), a leading biopharmaceutical company, has recently announced the grant of non-qualified stock option awards, restricted stock units (RSUs), and performance stock units (PSUs) to two non-executive employees. Effective from Februa...

Product Service News

Revolutionary New Treatment for Molluscum Contagiosum: First FDA-approved Topical Prescription Drug ZELSUVMI Takes Center Stage

Published Fri, Jan 5 2024 9:30 PM UTC

In an unprecedented move set to revolutionize the medical field, the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI (berdazimer topical gel, 10.3%) as a groundbreaking discovery for the treatment of molluscum contagiosum, a common yet widely untreated viral infection. Developed by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), an established entity on the...

Ligand Pharmaceuticals Incorporated

Enhancing the Sophistication: Ligand Pharmaceuticals Incorporated Reports Intensely Adverse Deterioration throughout the Fiscal Period Ending on September 30, 2023

Ligand Pharmaceuticals Incorporated is a pharmaceutical company that specializes in the discovery and development of innovative medicines. Based on the financial third quarter of 2023, the company experienced some significant changes in its financial performance.
One of the key indicators of a company's financial health is its earnings per share (EPS). In the financial third quarter of 2023, Ligand Pharmaceuticals slipped into a deficit of -$0.59 per share, compared to a positive EPS of $0.02 the previous year. This decline is concerning and may be attributed to various factors such as increased costs or decreased revenue.

Ligand Pharmaceuticals Incorporated

Severe Hit Shakes Ligand Pharmaceuticals Incorporated as Fiscal Year Ends with Mixed Performance

Ligand Pharmaceuticals Incorporated, a major player in the pharmaceutical industry, recently reported its financial results for the fiscal period ending June 30, 2023. These results reveal a mixed performance for the company, with positives and negatives impacting its operations. This article analyzes the key findings and assesses their potential implications for Ligand Pharmaceuticals going forward.
Positive Profits and Net Income Improvement:
Ligand Pharmaceuticals experienced a significant turnaround in profits, recording a positive $0.13 per share compared to a loss of $-0.05 in the previous year. Moreover, the company achieved net profits of $2.290 million, showcasing a remarkable improvement from a net shortfall of $-0.895 million in the corresponding quarter a year ago. These figures indicate a positive trajectory for Ligand Pharmaceuticals, suggesting increased efficiency and better financial stability.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated Bounces Back with Stunning Profit Rise amidst Industry Setbacks

Ligand Pharmaceuticals Incorporated, a major pharmaceutical preparations company, has recently turned a corner by posting a profit for the fiscal season ending March 31, 2023. This is a significant improvement from the prior fiscal season, where the company had a net deficit of $-15.385 million. In the most recent fiscal season, Ligand Pharmaceuticals Incorporated posted an EPS of $2.33 per share, compared to $-0.91 per share the prior year. Additionally, income per share turned positive, rising from $-1.04 per share to $2.33 per share.
While the revenue for Ligand Pharmaceuticals Incorporated contracted slightly by -3.751% to $43.98 million from $45.69 million in the prior reporting season, the company saw an impressive sequential revenue surge of 62.614%, rising from $27.05 million. The company also emphasized its improving profit margins, with a net margin rising to 95.38% in the fiscal season ending March 31, 2023, and an operating margin increasing to 32.3%.


Ligand Pharmaceuticals Incorporated's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com